Ipamorelin (NNC 26-0161)

1. Chemical Identification & Molecular Structure

Ipamorelin (NNC 26-0161) is a synthetic pentapeptide growth hormone-releasing peptide (GHRP) distinguished by its high selectivity for the growth hormone secretagogue receptor type 1a (GHS-R1a) (Raun et al., 1998). Classified as a synthetic ghrelin mimetic, Ipamorelin demonstrates selective growth hormone (GH) secretion without concurrent elevation of adrenocorticotropic hormone (ACTH), cortisol, or prolactin—a critical distinction from earlier GHRP analogs such as GHRP-6 and GHRP-2.

The pentapeptide sequence (Aib-His-D-2-Nal-D-Phe-Lys-NH2) incorporates both natural and modified amino acids, including alpha-aminoisobutyric acid (Aib) at the N-terminus and D-enantiomer naphthylalanine (D-2-Nal) and phenylalanine (D-Phe) residues at positions 3 and 4. With a molecular weight of 711.86 g/mol, these strategic D-amino acid substitutions prevent rapid enzymatic cleavage by endogenous peptidases while optimizing receptor binding affinity for GHS-R1a on anterior pituitary somatotrophs. Understanding peptide mechanisms and peptide research applications provides context for how these structural optimizations extend half-life relative to unmodified endogenous peptides.

2. GHS-R1a Receptor Activation & Pituitary Somatotroph Cell Dynamics

Ipamorelin functions as a selective agonist at GHS-R1a, a G-protein-coupled receptor (GPCR) predominantly expressed in somatotroph cells of the anterior pituitary gland. Receptor binding initiates intracellular signaling cascades mediated through G_q/11 proteins, facilitating GDP-GTP exchange and dissociation of activated G_q/11 subunits to activate phospholipase C-beta (PLC-β) isoforms. PLC-β hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP₂) to generate the second messengers inositol 1,4,5-trisphosphate (IP₃) and diacylglycerol (DAG), which respectively mobilize endoplasmic reticulum calcium stores and activate protein kinase C (PKC) isoforms.

The resulting elevation in intracellular calcium concentration ([Ca²⁺]_i) from approximately 100 nM to 500–1000 nM triggers fusion of growth hormone secretory vesicles with the plasma membrane. Electrophysiological studies of isolated somatotroph cells demonstrate that Ipamorelin induces characteristic calcium oscillations and membrane depolarization patterns consistent with physiological pulsatile growth hormone release, a key consideration in peptide dosing methodology.

3. Pharmacokinetics, Dose-Response Relationships & Inter-Individual Variability

Following subcutaneous administration, Ipamorelin demonstrates rapid absorption with peak plasma concentrations (C_max) achieved within 30–60 minutes post-injection. The absorption half-life approximates 15–20 minutes, while the terminal elimination half-life ranges from 90–120 minutes depending on dose and individual metabolic factors. Distribution studies indicate a volume of distribution consistent with extracellular fluid distribution, with moderate protein binding, peptidase-mediated hydrolysis as the primary metabolic pathway, and renal elimination as the principal clearance route. Pharmacodynamic modeling demonstrates dose-dependent growth hormone elevation, with peak GH concentrations typically occurring 30–45 minutes post-administration and returning toward baseline within 3–4 hours (Gobburu et al., 1999).

Published pharmacodynamic research describes a dose-dependent GH response with substantial inter-individual variability; it does not establish a universal human regimen (Gobburu et al., 1999). Importantly, the dose-response curve for GH secretion does not parallel dose-response curves for hunger stimulation or cortisol elevation. Inter-individual variability in GH response is influenced by age, body composition, baseline GH secretory status, and circadian timing, with older subjects and individuals with obesity exhibiting attenuated somatotroph responses compared with younger, lean cohorts.

4. Endocrinology Research Context: Adult GH Deficiency, Somatopause & Catabolic States

Ipamorelin has been investigated in several clinical contexts involving suboptimal growth hormone secretion:

• Adult Growth Hormone Deficiency (AGHD): In AGHD research, Ipamorelin has been studied as an investigational approach to stimulating endogenous pulsatile GH production rather than replacing it with exogenous recombinant human growth hormone (rhGH), preserving negative feedback regulatory mechanisms. While studies have demonstrated measurable increases in serum IGF-1 and improvements in body composition markers, long-term comparative effectiveness trials against rhGH remain limited (Sigalos et al., 2021).
• Age-Related Somatopause: Epidemiological data show that endogenous GH secretion declines approximately 14% per decade after age 20. Clinical studies in older adults indicate that Ipamorelin stimulates GH release, though response amplitude is attenuated compared with younger subjects and long-term safety and efficacy data do not support routine clinical use outside controlled research settings (see Safety Protocols).
• Catabolic States & Critical Illness: Preclinical models of surgical stress and critical illness have reported reduced nitrogen loss, preservation of lean body mass, and enhanced markers of protein synthesis with Ipamorelin. Translation to human critical illness outcomes requires further investigation.

5. Safety Profile & Endocrine Selectivity Compared to Other GHRPs

Comparative pharmacology studies (Raun et al., 1998; Johansen et al., 1999) document Ipamorelin's refined selectivity relative to first- and second-generation GHRPs (GHRP-6 and GHRP-2), which activate broader neuroendocrine pathways resulting in concurrent elevation of ACTH, cortisol, and prolactin alongside growth hormone. At equipotent exposures for GH stimulation, Ipamorelin produces no significant elevation of plasma cortisol, ACTH, or prolactin, preserving the physiological GH-to-cortisol ratio.

Adverse Event Profile & Contraindications: In clinical safety evaluations, reported adverse events are generally mild and self-limiting, including mild injection-site erythema or transient discomfort, transient appetite increases in some subjects, and occasional headache or dizziness (see Adverse Event Literature). Because most clinical studies span weeks to months rather than years, long-term safety data regarding chronic GH/IGF-1 elevation remain an ongoing research priority. Theoretical contraindications and precautions include active malignancy, diabetes mellitus or impaired glucose tolerance (requiring glycemic monitoring due to GH-mediated insulin resistance), active critical illness outside controlled protocols, pregnancy, lactation, and pediatric use outside approved trials.

6. Synergistic Mechanisms with GHRH Analogs

Whereas GHRH analogs (Sermorelin or CJC-1295) bind pituitary GHRH receptors to activate adenylyl cyclase via G_s proteins, elevating cAMP and activating protein kinase A (PKA), Ipamorelin activates phospholipase C via G_q/11 proteins at GHS-R1a. Co-administration of Ipamorelin with GHRH analogs produces growth hormone responses 1.5- to 3-fold greater than the arithmetic sum of responses to the individual compounds by converging on calcium mobilization, membrane depolarization, and secretory granule exocytosis. Research protocols investigating this dual-pathway convergence examine equimolar ratios and simultaneous administration timing within controlled institutional frameworks (see Multi-Peptide Co-Administration).

7. Metabolic and Body Composition Effects

Clinical investigations in adults with relative growth hormone insufficiency have reported that Ipamorelin administration over 8–24 weeks is associated with measurable increases in lean body mass (typically 1–3 kg) and reductions in fat mass (1–2 kg), with effects correlating with serum IGF-1 changes and baseline somatotropic status (Laron, 2019). Stable isotope tracer and metabolic balance studies indicate that pulsatile GH elevation shifts whole-body protein turnover toward net anabolism and positive nitrogen balance, while activating adipocyte hormone-sensitive lipase to mobilize triglycerides preferentially from visceral adipose depots relative to subcutaneous fat.

8. Regulatory Status, Anti-Doping Classification & Future Research Directions

• FDA Regulatory Status (as of April 22, 2026): Ipamorelin is an unapproved investigational compound and has not completed Phase III trials for FDA marketing approval (Clemmons et al., 2014). On FDA's bulk drug substances page current as of April 22, 2026, ipamorelin acetate remains in Category 2 (503B) and also appears in the withdrawn nominations table; withdrawal of a nomination is not FDA approval or clearance.
• WADA Prohibited List: Ipamorelin and all growth hormone secretagogues are prohibited at all times (in- and out-of-competition) under Section S2 of the World Anti-Doping Agency Prohibited List, with validated LC-MS detection assays for parent peptide and metabolites in blood and urine.
• Future Research & Clinical Governance: Priority research areas include long-term safety and efficacy studies in sarcopenic obesity, HIV-associated lipodystrophy, and postoperative recovery; pharmacogenomic, proteomic, and metabolomic biomarker validation; alternative non-parenteral (oral, nasal, transdermal) and biodegradable depot delivery systems (see Storage & Stability Science); and adherence to Good Clinical Practice (GCP), IRB oversight, and informed consent standards (Devlin & Cloutier, 2016). Additional context is available in our Epithalon, TB-500, GHK-Cu, and FAQ reference pages.

9. References

1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822 (Source link)
2. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. PMID: 10373343 (Source link)
3. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PMID: 10496658
4. Sigalos JT, Pastuszak AW, Khera M. The Use of Peptide Hormones in Sports and Wellness. Sex Med Rev. 2021;9(2):292-299. PMID: 32418878
5. Laron Z. Growth hormone therapy: Emerging dilemmas. Pediatr Endocrinol Rev. 2019;16(3):367-373. PMID: 30840453
6. Clemmons DR, Molitch M, Hoffman AR, Katznelson L, Chanson P, Woodmansee WW, Trainer P. Growth hormone should be used only for approved indications. J Clin Endocrinol Metab. 2014;99(2):409-411. PMID: 24471023
7. Devlin MJ, Cloutier AM. Growth hormone and peptide-based therapeutic use: Current status and future prospects. Endocr Pract. 2016;22(3):352-360. PMID: 26684130
8. Nass R, Thorner MO. Impact of the GH-cortisol ratio on the age-dependent changes in body composition. Growth Horm IGF Res. 2002;12(3):147-161. PMID: 12175645 (Source link) (Source link)
9. Veldhuis JD, Keenan DM, Pincus SM. Motivations and methods for analyzing pulsatile hormone secretion. Endocr Rev. 2008;29(7):823-864. PMID: 18940916 (Source link)
10. Kojima M, Kangawa K. Ghrelin: Structure and function. Physiol Rev. 2005;85(2):495-522. PMID: 15788704 (Source link)
11. Giustina A, Barkan A, Beckers A, et al. A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. J Clin Endocrinol Metab. 2020;105(4):e937-e946. PMID: 31930374 (Source link)
12. Bartke A. Growth hormone and aging: Updated review. World J Mens Health. 2019;37(1):19-30. PMID: 30209909 (Source link)